Pfizer: a controversial outlook

Pfizer: a controversial outlook

2021-02-01 • Updated

Pfizer reports its Q4’2020 performance on Tuesday, at 17:00 MT time.

Its EPS is expected to be within the range of $0.45-0.50. Will Pfizer manage to beat the forecast? There are mixed reviews on that. In Q4, Pfizer completed the separation of the Upjohn unit to form “New Pfizer”. Sales of its primary medications have been pretty good during the months September-December. However, some particular products have declined. In addition, the disruption of doctor visits and related healthy activities around the world may have brought significant damage as well. That’s why observers are very moderate with optimism on Pfizer. The same controversy appears when you look at the chart.

The long-term view doesn’t suggest any firm uptrend. Rather, a continuous oscillation and mid-term friction. While the 2007-2018 performance has been a steady uptrend that ended at the highs above $43, the recent years did favor this stock too much. It met the Covid-19 era at the lows of $28. Thanks to the vaccine, it rose to $43 – the entrance to the highest-ever area where it was in 2018 and 2002. However, the vaccine rush seems to have cooled off, and the stock price doesn’t seem to be in an uptrend.

Therefore, in the scenario of weak performance, bears will likely drag it below $35, and the nearest mid-term will likely see it between $32 and $35.

Otherwise, if Pfizer manages to give a positive surprise to investors against the expected EPS of $0.45, the stock may reverse to the upside and get pushed to approach $43 again.

PFIZERWeekly.png

Don't know how to trade stocks? Here are some simple steps.

  1. First of all, be sure you’ve downloaded Metatrader 5 or FBS Trader app. FBS allows you to trade stocks only through this software.
  2. Open the MT5 account in your personal area (in account in FBS Trader)
  3. Start trading!

                                                                                                   LOG IN

Similar

Nasdaq 100 (US100): Toward 17750
Nasdaq 100 (US100): Toward 17750

Bullish Scenario: Buy between 17515 and 17600 with TP1: 17681; TP2: 17720 intraday, and TP3: 17750 / 18000 in extension. Bearish Scenario in case of breaking the buying zone: Sell below 17500 with TP1: 17469; TP2: 17421, and TP3: 17358 in extension.

Latest news

XAUUSD: Bears Prepare To Takeover
XAUUSD: Bears Prepare To Takeover

On Friday, the gold price (XAUUSD) retreated from a recent two-week high, facing selling pressure. This decline was driven by hawkish minutes from the FOMC meeting, indicating the Fed's reluctance to cut interest rates. Elevated US Treasury bond yields, supported by a "higher-for-longer" narrative, further weakened demand for gold...

Deposit with your local payment systems

Data collection notice

FBS maintains a record of your data to run this website. By pressing the “Accept” button, you agree to our Privacy policy.

Callback

A manager will call you shortly.

Change number

Your request is accepted.

A manager will call you shortly.

Next callback request for this phone number
will be available in

If you have an urgent issue please contact us via
Live chat

Internal error. Please try again later

Don’t waste your time – keep track of how NFP affects the US dollar and profit!

You are using an older version of your browser.

Update it to the latest version or try another one for a safer, more comfortable and productive trading experience.

Safari Chrome Firefox Opera